NCT07050043 2025-07-03
LEDANG
Hospital Sultanah Bahiyah
Phase 3 Recruiting
Clinical Trials
17 trialsNCT03914443 2025-05-31
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
National Cancer Center, Japan
Phase 1 Completed
NCT04463368 2025-03-28
SCANDIUM II
Vastra Gotaland Region
Phase 1 Completed
NCT06519266 2024-11-25
SCANDIUM-III
Vastra Gotaland Region
Phase 3 Recruiting
NCT06693440 2024-11-18
The Immune Assessment of PD-1 Antibody Therapy in Tumor
Henan Cancer Hospital
Recruiting
NCT03245021 2024-07-30
1stFLOR
Austin Health
Phase 1 Active not recruiting
NCT03685890 2024-04-25
NivoILP
Vastra Gotaland Region
Phase 1/2 Recruiting
NCT05088889 2023-11-28
Maintenance Ipilimumab + Nivolumab Post Induction Chemotherapy + SBRT for First Line Treatment Stage IV Pancreatic Cancer
Sheba Medical Center
Phase 1 Unknown
NCT03166397 2023-01-26
Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients
Sheba Medical Center
Phase 2 Recruiting
NCT05385263 2022-05-26
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
Tel-Aviv Sourasky Medical Center
Phase 2 Unknown
NCT03808480 2022-04-06
Nivolumab After Cyclophosphamide and Doxorubicin Induction Therapy in NSCLC With PD-L1<10%
National Cancer Center, Korea
Phase 2 Unknown
NCT05001360 2021-10-27
Study of FMT Combined With Nivolumab in Gastric Cancer
Fujian Cancer Hospital
Phase NA Withdrawn
NCT04142931 2021-03-24
Sequentional Immuno Apheresis Plasma Volume Escalation Cohort Study of Reduction of Soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) With or Without Nivolumab in Patients With Inoperable or Metastatic Solid Tumors
Sheba Medical Center
Phase 1 Unknown
NCT04331626 2020-04-02
Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC
Henan Cancer Hospital
Phase 4 Unknown
NCT02999295 2019-08-21
A Phase 1/2 Study of Ramucirumab Plus Nivolumab in Participants With Gastric or GEJ Cancer
National Cancer Center, Japan
Phase 1/2 Completed
NCT03569696 2019-04-23
NivoM
Sheba Medical Center
Phase 2 Unknown
NCT02982486 2017-11-01
A Phase II of Nivolumab Plus Ipilimumab in Non-resectable Sarcoma and Endometrial Carcinoma
Assaf-Harofeh Medical Center
Phase 2 Unknown